[HTML][HTML] Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation

HPJ Van der Doef, FTM Kokke, CK van der Ent… - Current …, 2011 - Springer
Meconium ileus at birth, distal intestinal obstruction syndrome (DIOS), and constipation are
an interrelated group of intestinal obstruction syndromes with a variable severity of …

[HTML][HTML] A new era for people with cystic fibrosis

MC Bierlaagh, D Muilwijk, JM Beekman… - European Journal of …, 2021 - Springer
Cystic fibrosis is the most prevalent inherited disease caused by a defect in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. The impaired electrolyte homeostasis …

[HTML][HTML] Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients

G Schwank, BK Koo, V Sasselli, JF Dekkers, I Heo… - Cell stem cell, 2013 - cell.com
Single murine and human intestinal stem cells can be expanded in culture over long time
periods as genetically and phenotypically stable epithelial organoids. Increased cAMP …

A functional CFTR assay using primary cystic fibrosis intestinal organoids

JF Dekkers, CL Wiegerinck, HR De Jonge… - Nature medicine, 2013 - nature.com
We recently established conditions allowing for long-term expansion of epithelial organoids
from intestine, recapitulating essential features of the in vivo tissue architecture. Here we …

Long‐term expanding human airway organoids for disease modeling

N Sachs, A Papaspyropoulos… - The EMBO …, 2019 - embopress.org
Organoids are self‐organizing 3D structures grown from stem cells that recapitulate
essential aspects of organ structure and function. Here, we describe a method to establish …

[HTML][HTML] Readthrough compounds for nonsense mutations: bridging the translational gap

S Spelier, EPM van Doorn, CK van der Ent… - Trends in molecular …, 2023 - cell.com
Approximately 10% of all pathological mutations are nonsense mutations that are
responsible for several severe genetic diseases for which no treatment regimens are …

[HTML][HTML] Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del

JL Taylor-Cousar, A Munck, EF McKone… - New england journal …, 2017 - Mass Medical Soc
Background Combination treatment with the cystic fibrosis transmembrane conductance
regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to …

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

JF Dekkers, G Berkers, E Kruisselbrink… - Science translational …, 2016 - science.org
Identifying subjects with cystic fibrosis (CF) who may benefit from cystic fibrosis
transmembrane conductance regulator (CFTR)–modulating drugs is time-consuming, costly …

[PDF][PDF] Rectal organoids enable personalized treatment of cystic fibrosis

G Berkers, P van Mourik, AM Vonk, E Kruisselbrink… - Cell reports, 2019 - cell.com
In vitro drug tests using patient-derived stem cell cultures offer opportunities to individually
select efficacious treatments. Here, we provide a study that demonstrates that in vitro drug …

Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study

PHC Klijn, A Oudshoorn, CK van der Ent, J van der Net… - Chest, 2004 - Elsevier
Background Children's physical activity patterns are characterized by short-term anaerobic
activities. Anaerobic exercise performance in children with cystic fibrosis (CF) has received …